Reactive oxygen intermediates enhance Fc gamma receptor signaling and amplify phagocytic capacity.
Receptors for the Fc region of IgG (Fc gamma R) mediate internalization of opsonized particles by human neutrophils (PMN) and mononuclear phagocytes. Cross-linking of Fc gamma R leads to activation of protein tyrosine kinases and phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) within Fc gamma R subunits, both obligatory early signals for phagocytosis. Human PMN constitutively express two structurally distinct Fc gamma R, Fc gamma RIIa and Fc gamma RIIIb, and can be induced to express Fc gamma RI by IFN-gamma. We have previously shown that stimulation of PMN through Fc gamma RIIIb results in enhanced Fc gamma RIIa-mediated phagocytic activity that is inhibited by catalase. In the present study, we have tested the hypothesis that reactive oxygen intermediates (ROI) have the capacity to regulate Fc gamma R responses and defined a mechanism for this effect. We show that H2O2 augmented phagocytosis mediated by Fc gamma RIIa and Fc gamma RI in PMN and amplified receptor-triggered tyrosine phosphorylation of Fc gamma R-associated ITAMs and signaling elements. Generation of endogenous oxidants in PMN by cross-linking Fc gamma RIIIb similarly enhanced phosphorylation of Fc gamma RIIa and Syk, a tyrosine kinase required for phagocytic function, in a catalase-sensitive manner. Our results provide a mechanism for priming phagocytes for enhanced responses to receptor-driven effects. ROI generated in an inflammatory milieu may stimulate quiescent cells to rapidly increase the magnitude of their effector function. Indeed, human monocytes incubated in the presence of stimulated PMN showed oxidant-induced increases in Fc gamma RIIa-mediated phagocytosis. Definition of the role of oxidants as amplifiers of Fc gamma R signaling identifies a target for therapeutic intervention in immune complex-mediated tissue injury.
Pricop
L
L
Department of Medicine, Hospital for Special Surgery, New York Presbyterian Hospital, Graduate Program in Immunology, Weill Medical College of Cornell University, New York 10021, USA.
Gokhale
J
J
Redecha
P
P
Ng
S C
SC
Salmon
J E
JE
D000276:Adjuvants, Immunologic / Q000378:metabolism / Q000502:physiology; D002460:Cell Line; D004792:Enzyme Precursors / Q000378:metabolism; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D009000:Monocytes / Q000276:immunology; D009504:Neutrophils / Q000276:immunology / Q000378:metabolism; D016877:Oxidants / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology; D010587:Phagocytosis / Q000276:immunology*; D010766:Phosphorylation / Q000187:drug effects; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000276:immunology / Q000378:metabolism / Q000502:physiology*; D017452:Receptors, IgG / Q000378:metabolism / Q000502:physiology*; D015398:Signal Transduction / Q000276:immunology*; D000072377:Syk Kinase; D014443:Tyrosine / Q000378:metabolism; D020298:U937 Cells
D000276:Adjuvants, Immunologic; D004792:Enzyme Precursors; D047908:Intracellular Signaling Peptides and Proteins; D016877:Oxidants; D017382:Reactive Oxygen Species; D017452:Receptors, IgG; D014443:Tyrosine; D011505:Protein-Tyrosine Kinases; C000606896:SYK protein, human; D000072377:Syk Kinase